ACAD Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:

Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY

2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY

BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las Vegas, NV

Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507861038/en/

Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 ir@acadia-pharm.com

Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950 ir@acadia-pharm.com

Acadia Pharmaceuticals (NASDAQ:ACAD)
過去 株価チャート
から 2 2025 まで 3 2025

Acadia Pharmaceuticals (NASDAQ:ACAD)
過去 株価チャート
から 3 2024 まで 3 2025